Ketamine
Ketalar (ketamine) is a small molecule pharmaceutical. Ketamine was first approved as Ketalar on 1982-01-01. It is used to treat burns and pain in the USA. The pharmaceutical is active against glutamate receptor ionotropic, NMDA 2C, glutamate receptor ionotropic, NMDA 2A, glutamate receptor ionotropic, NMDA 2D, and glutamate receptor ionotropic, NMDA 2B.
Download report
Favorite
Searched
Commercial
Trade Name
FDA
EMA
Ketalar (generic drugs available since 1996-03-22)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ketamine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| KETALAR | Par Pharmaceutical | N-016812 RX | 1982-01-01 | 3 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ketalar | New Drug Application | 2022-12-22 |
| ketamine hydrochloride | ANDA | 2022-08-01 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| burns | — | D002056 | T30.0 |
| pain | EFO_0003843 | D010146 | R52 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| G2082 | Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of up to 56 mg of esketamine nasal self-administration, includes 2 hours post-administration observation |
| G2083 | Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of greater than 56 mg esketamine nasal self-administration, includes 2 hours post-administration observation |
| S0013 | Esketamine, nasal spray, 1 mg |
Clinical
Clinical Trials
994 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postoperative pain | D010149 | G89.18 | 5 | 16 | 19 | 41 | 26 | 96 | |
| Pain | D010146 | EFO_0003843 | R52 | 7 | 8 | 15 | 32 | 23 | 81 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 19 | 21 | 12 | 12 | 19 | 75 |
| Depression | D003863 | F33.9 | 16 | 21 | 7 | 13 | 12 | 63 | |
| Acute pain | D059787 | R52 | 2 | 7 | 8 | 17 | 14 | 43 | |
| Treatment-resistant depressive disorder | D061218 | 4 | 14 | 6 | 7 | 6 | 34 | ||
| Chronic pain | D059350 | HP_0012532 | 2 | 5 | 7 | 4 | 17 | 33 | |
| Healthy volunteers/patients | — | 23 | 3 | 1 | 3 | 4 | 33 | ||
| Anesthesia | D000758 | 3 | 2 | 5 | 13 | 8 | 30 | ||
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 5 | 7 | 6 | 5 | 8 | 29 |
Show 138 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 4 | 5 | 6 | — | 3 | 16 | |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | 3 | 8 | 2 | — | 1 | 12 |
| Morbid obesity | D009767 | EFO_0001074 | — | — | 2 | — | 3 | 5 | |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 1 | 2 | 2 | — | — | 4 |
| Cognitive dysfunction | D060825 | G31.84 | 2 | 2 | 1 | — | — | 4 | |
| Cocaine-related disorders | D019970 | F14 | 1 | 3 | 1 | — | — | 4 | |
| Mucositis | D052016 | EFO_1001898 | — | 2 | 2 | — | — | 4 | |
| Postoperative complications | D011183 | — | 1 | 2 | — | 1 | 3 | ||
| Bone fractures | D050723 | EFO_0003931 | T14.8 | — | 1 | 2 | — | — | 3 |
| Tonsillectomy | D014068 | 1 | 1 | 1 | — | — | 2 |
Show 39 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | 2 | 8 | — | — | 4 | 12 |
| Fatigue | D005221 | HP_0012378 | R53.83 | 3 | 3 | — | — | — | 4 |
| Head and neck neoplasms | D006258 | 2 | 3 | — | — | — | 4 | ||
| Complex regional pain syndromes | D020918 | EFO_1001998 | — | 2 | — | — | 1 | 3 | |
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | 1 | — | — | 1 | 2 |
| Magnetic resonance imaging | D008279 | 1 | 1 | — | — | — | 2 | ||
| Autism spectrum disorder | D000067877 | F84.0 | 1 | 1 | — | — | — | 2 | |
| Sepsis | D018805 | A41.9 | 1 | 1 | — | — | 1 | 2 | |
| Covid-19 | D000086382 | U07.1 | — | 1 | — | — | 1 | 2 | |
| Neurologic manifestations | D009461 | — | 1 | — | — | 1 | 2 |
Show 33 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 2 | — | — | — | 1 | 3 |
| Brachial plexus block | D065527 | 1 | — | — | — | 2 | 3 | ||
| Emotions | D004644 | 1 | — | — | — | 1 | 2 | ||
| Pharmacokinetics | D010599 | 1 | — | — | — | 1 | 2 | ||
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | — | — | — | — | 2 |
| Separation anxiety | D001010 | EFO_1001916 | 1 | — | — | — | — | 1 | |
| Pulmonary atelectasis | D001261 | J98.1 | 1 | — | — | — | — | 1 | |
| Biological availability | D001682 | 1 | — | — | — | — | 1 | ||
| Vital signs | D055986 | EFO_0004303 | 1 | — | — | — | — | 1 | |
| Cortical spreading depression | D013181 | 1 | — | — | — | — | 1 |
Show 17 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Nociceptive pain | D059226 | — | — | — | — | 4 | 4 | ||
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | — | — | — | 2 | 2 |
| Colorectal neoplasms | D015179 | — | — | — | — | 2 | 2 | ||
| Electroencephalography | D004569 | — | — | — | — | 2 | 2 | ||
| Hip fractures | D006620 | EFO_0003964 | S72.00 | — | — | — | — | 2 | 2 |
| Bariatric surgery | D050110 | — | — | — | — | 1 | 1 | ||
| Rhytidoplasty | D015361 | — | — | — | — | 1 | 1 | ||
| Arthritis | D001168 | EFO_0005856 | M05-M14 | — | — | — | — | 1 | 1 |
| Tendinopathy | D052256 | EFO_1001434 | M77.9 | — | — | — | — | 1 | 1 |
| Synovitis | D013585 | EFO_0008997 | M67.5 | — | — | — | — | 1 | 1 |
Show 41 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | KETAMINE |
| INN | ketamine |
| Description | Ketamine is a member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group. It has a role as an intravenous anaesthetic, a NMDA receptor antagonist, an analgesic, a neurotoxin, an environmental contaminant and a xenobiotic. It is a member of cyclohexanones, a secondary amino compound and a member of monochlorobenzenes. |
| Classification | Small molecule |
| Drug class | NMDA receptor antagonists; General anesthetics; Dissociative hallucinogens; Analgesics; Antidepressants |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CNC1(c2ccccc2Cl)CCCCC1=O |
Identifiers
| PDB | — |
| CAS-ID | 6740-88-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL742 |
| ChEBI ID | 6121 |
| PubChem CID | 3821 |
| DrugBank | DB01221 |
| UNII ID | 690G0D6V8H (ChemIDplus, GSRS) |
Target
Agency Approved
GRIN2C
GRIN2C
GRIN2A
GRIN2A
GRIN2D
GRIN2D
GRIN2B
GRIN2B
Organism
Homo sapiens
Gene name
GRIN2C
Gene synonyms
NMDAR2C
NCBI Gene ID
Protein name
glutamate receptor ionotropic, NMDA 2C
Protein synonyms
GluN2C(alt_5'UTR_77nt), GluN2C(alt_5'UTR_87nt), GluN2C(del_e2), GluN2C-b alternative isoform, Glutamate [NMDA] receptor subunit epsilon-3, glutamate receptor, ionotropic, N-methyl D-aspartate 2C, N-methyl D-aspartate receptor subtype 2C, N-methyl-D-aspartate receptor subunit 2C, NMDAR2C, NR2C, putative NMDtranscript(altAcc_e11), putative NMDtranscript(altDon_e4), putative NMDtranscript(del_e4)
Uniprot ID
Mouse ortholog
Grin2c (14813)
glutamate receptor ionotropic, NMDA 2C (Q01098)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 144,055 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
29,349 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more